Example: Heart Attack

Clinical Trials Sponsored by Wilex

Total 9 results

NCT01859351

Terminated

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Conditions: Advanced Solid Tumours
NCT01762592

Withdrawn

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Conditions: Renal Cell Carcinoma; Kidney Cancer
NCT01581060

Terminated

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

Conditions: Advanced Solid Tumours
NCT00615940

Completed

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT00606632

Completed

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Conditions: Renal Cell Carcinoma; Kidney Cancer
NCT00499265

Completed

Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Conditions: Pancreatic Cancer
NCT00087022

Completed

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Conditions: Kidney Cancer
NCT00083525

Completed

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Conditions: Advanced Malignancies
NCT00520533

Terminated

Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Conditions: Renal Cell Carcinoma